TY - JOUR
AR - COR-2019-5-115
TI - Mitotic Count and Estimation of the Risk of GIST Recurrence in Patients Treated with Preoperative Imatinib
AU - Heikki, Joensuu
AU - Mikael, Eriksson
JO - Clinical Oncology and Research
PY - 2019
DA - Mon 30, Dec 2019
SN - 2613-4942
DO - http://dx.doi.org/10.31487/j.COR.2019.5.15
UR - https://www.sciencerepository.org/mitotic-count-and-estimation-of-the-risk-of-gist-recurrence_COR-2019-5-115 
KW - GIST, imatinib, neoadjuvant therapy, adjuvant therapy, risk prediction
AB - Preoperative imatinib is used frequently in the treatment of large localized GISTs to shrink the tumor prior
to surgery. This approach may lead to challenges in the estimation of the risk of recurrence and the need
of adjuvant imatinib, because the diagnosis is usually made from a needle biopsy with scant tissue for the
assessment of GIST mitotic activity, a key prognostic factor. We propose a mitosis count multiplication
method as a proxy for estimating the tumor mitotic count in select cases.